Analyst Price Targets — ELVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 18, 2026 11:02 am | Salim Syed | Mizuho Securities | $73.00 | $59.54 | TheFly | Enliven price target raised to $73 from $62 at Mizuho |
| August 18, 2026 9:14 am | Etzer Darout | Barclays | $78.00 | $59.54 | TheFly | Enliven initiated with an Overweight at Barclays |
| August 6, 2026 12:21 pm | Dara Azar | Stifel Nicolaus | $82.00 | $60.68 | TheFly | Enliven price target raised to $82 from $80 at Stifel |
| August 6, 2026 10:44 am | Michael Schmidt | Guggenheim | $78.00 | $59.70 | StreetInsider | Enliven Therapeutics (ELVN) PT Lowered to $78 at Guggenheim |
| August 6, 2026 10:14 am | — | Goldman Sachs | $80.00 | $59.70 | TheFly | Enliven price target raised to $80 from $67 at Goldman Sachs |
| July 21, 2026 9:51 am | Salveen Richter | Goldman Sachs | $67.00 | $51.67 | TheFly | Enliven price target raised to $67 from $59 at Goldman Sachs |
| July 9, 2026 10:05 am | Robert Burns | H.C. Wainwright | $65.00 | $50.80 | TheFly | Enliven price target raised to $65 from $56 at H.C. Wainwright |
| July 1, 2026 12:26 pm | — | Stifel Nicolaus | $80.00 | $50.68 | TheFly | Enliven price target raised to $80 from $60 at Stifel |
| June 8, 2026 8:10 pm | — | Stifel Nicolaus | $60.00 | $33.63 | TheFly | Enliven initiated with a Buy at Stifel |
| June 2, 2026 10:41 am | Salim Syed | Mizuho Securities | $62.00 | $37.51 | StreetInsider | Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho |
Latest News for ELVN
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO)…
BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,359,704 shares of the company's stock, valued at approximately $221,255,000. BlackRock Inc. owned 7.16% of Enliven Therapeutics at
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
Dimensional Fund Advisors LP lifted its position in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) by 70.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 681,715 shares of the company's stock after acquiring an additional 282,822 shares during the quarter. Dimensional Fund Advisors LP
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignment with the FDA on key Phase 3 trial design components Strong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030 BURLINGAME, Calif., Aug. 5, 2026 /PRNewswire/…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELVN.
U.S. House Trading
No House trades found for ELVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.